[go: up one dir, main page]

MA51297B1 - Quinazolinones en tant qu'inhibiteurs de parp14 - Google Patents

Quinazolinones en tant qu'inhibiteurs de parp14

Info

Publication number
MA51297B1
MA51297B1 MA51297A MA51297A MA51297B1 MA 51297 B1 MA51297 B1 MA 51297B1 MA 51297 A MA51297 A MA 51297A MA 51297 A MA51297 A MA 51297A MA 51297 B1 MA51297 B1 MA 51297B1
Authority
MA
Morocco
Prior art keywords
quinazolinones
parp14
inhibitors
parp14 inhibitors
cancer
Prior art date
Application number
MA51297A
Other languages
English (en)
Other versions
MA51297A (fr
Inventor
Kevin Wayne Kuntz
Laurie B Schenkel
Melissa Marie Vasbinder
Kerren Kalai Swinger
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Priority claimed from PCT/US2018/066700 external-priority patent/WO2019126443A1/fr
Publication of MA51297A publication Critical patent/MA51297A/fr
Publication of MA51297B1 publication Critical patent/MA51297B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des quinazolinones et des composés apparentés qui sont des inhibiteurs de parp14 et sont utiles, par exemple, dans le traitement du cancer et de maladies inflammatoires.
MA51297A 2017-12-21 2018-12-20 Quinazolinones en tant qu'inhibiteurs de parp14 MA51297B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762608747P 2017-12-21 2017-12-21
PCT/US2018/066700 WO2019126443A1 (fr) 2017-12-21 2018-12-20 Quinazolinones en tant qu'inhibiteurs de parp14

Publications (2)

Publication Number Publication Date
MA51297A MA51297A (fr) 2020-10-28
MA51297B1 true MA51297B1 (fr) 2023-01-31

Family

ID=71842911

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51297A MA51297B1 (fr) 2017-12-21 2018-12-20 Quinazolinones en tant qu'inhibiteurs de parp14

Country Status (2)

Country Link
AR (1) AR114003A1 (fr)
MA (1) MA51297B1 (fr)

Also Published As

Publication number Publication date
AR114003A1 (es) 2020-07-08
MA51297A (fr) 2020-10-28

Similar Documents

Publication Publication Date Title
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MA45029A (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
EA202091709A1 (ru) Ингибиторы днк-пк
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MA43335B1 (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA55434A (fr) Compositions comprenant des souches bactériennes
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA41010B1 (fr) Compositions comprenant des souches bactériennes
MA40132A1 (fr) Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
EA201892714A1 (ru) Имидазолиновые соединения в качестве ингибиторов эластазы нейтрофилов человека
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
MA52920B1 (fr) Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f
EA201791937A1 (ru) Противовоспалительные полипептиды
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MA51297B1 (fr) Quinazolinones en tant qu'inhibiteurs de parp14
EA202091524A1 (ru) Ингибиторы рецептора, активируемого протеазой 2
EA202091542A1 (ru) Хиназолиноны в качестве ингибиторов parp14
EA201990393A1 (ru) Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-